N@N

AMYLIN PHARMACEUTICALS, INC. (NASDAQ:AMLN), Up By 10.41% ($2.90) From $27.850 After BUYINS.NET Report Predicted Strength Before

^{Published on 2012-07-03 07:45:16 - WOPRAI}
 

July 3, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, June 19th 2012 stating that AMYLIN PHARMACEUTICALS, INC. (NASDAQ:AMLN) was expected to be Up Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=amln&id=285915

At the time this story was written, AMYLIN PHARMACEUTICALS, INC. (NASDAQ:AMLN) is Up By 10.41% ($2.90) From $27.850 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

AMYLIN PHARMACEUTICALS, INC. (NASDAQ:AMLN) - Amylin Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. The companys products include BYETTA (exenatide) injection for the treatment of type 2 diabetes; and SYMLIN (pramlintide acetate) injection for the treatment of type 1 and type 2 diabetes. It also has research and development (R&D) programs in the therapeutic areas of diabetes and obesity. The companys R&D programs for diabetes include exenatide once weekly, exenatide once weekly pen, exenatide suspension formulation, exenatide nasal, and the exenatide transdermal patch. Its R&D programs for obesity comprise pramlintide/metreleptin combination therapy and PYY 3-36. The company markets its products to healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers, and other third-party payers primarily in the United States. It has collaboration agreements Eli Lilly and Company; Alkermes, Inc.; Takeda Pharmaceutical Company Limited; Biocon, Ltd.; and BioSeek, Inc. The company was founded in 1987 and is based in San Diego, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. AMYLIN PHARMACEUTICALS, INC. (NASDAQ:AMLN) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net